OGN Stock Recent News

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organon stock experienced significant downside pressure in 2023, however positive Q423 and Q124 earnings have led to a bull run. Organon's business includes women's health, biosimilars, and established brands divisions. The company was spun out of Merck & Co in 2020, and saddled with >$8bn debt. I anticipate Organon's upcoming Q2 2024 earnings will underline growth potential, with a focus on global sales, new product performance, and solid debt management.

Organon (OGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

In the closing of the recent trading day, Organon (OGN) stood at $20.81, denoting a +0.39% change from the preceding trading day.

In the most recent trading session, Organon (OGN) closed at $19.93, indicating a -1.04% shift from the previous trading day.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will report Q2 2024 results and host conference call on August 6, 2024. Organon estimates $15M milestone expenses in second quarter.

In the most recent trading session, Organon (OGN) closed at $20.63, indicating a -0.77% shift from the previous trading day.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Organon (OGN) closed the most recent trading day at $20.45, moving +0.49% from the previous trading session.